By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Janssen Pharmaceutical Inc.  

1125 Trenton-Harbourton Road

Titusville  New Jersey  08560  U.S.A.
Phone: 609-730-2000 Fax: n/a



Company News
Janssen Pharmaceutical Release: U.S. FDA Expands Indication of INVOKAMET (Canagliflozin/Metformin Hcl) To Include First-Line Treatment Of Adults With Type 2 Diabetes 5/24/2016 6:36:01 AM
Cue Announces Collaboration With Johnson & Johnson (JNJ) And Johnson & Johnson Innovation (JNJ) To Accelerate Development Of Quantitative HIV Viral Load Test For Resource Poor Settings 2/4/2016 11:15:59 AM
ChemDiv, Inc. Announces Achievement Of A Development Milestone In A Drug Discovery Collaboration With Janssen Pharmaceutical 1/12/2016 12:40:50 PM
Evotec AG (EVTG.F) Achieves Important Milestone In TargetAD Collaboration With Janssen Pharmaceutical In Alzheimer's Disease 1/12/2016 12:10:54 PM
Janssen Pharmaceutical, Medivir (MVRBF) Terminate AL-704 Phase I for Treatment of Hepatitis C 12/21/2015 6:24:41 AM
Bavarian Nordic (BAVA.CO), Janssen Pharmaceutical Strike $171 Million HPV Vaccine Pact 12/18/2015 8:48:01 AM
Janssen Pharmaceutical Release: Real-World Data Confirms Safety And Efficacy Profile Of XARELTO, With Shorter Hospital Stays, For The Treatment Of Deep Vein Thrombosis 12/8/2015 9:34:01 AM
Aduro Biotech (ADRO) Receives Milestone Payment From Janssen Pharmaceutical For Submission Of Investigational New Drug Application For ADU-741 In Prostate Cancer 11/18/2015 7:26:03 AM
Medivir (MVRBF) Announces That Janssen Pharmaceutical Has Started A Phase IIa Study To Evaluate The Effect Of Simeprevir In Combination With Odalasvir And AL-335 10/16/2015 11:05:18 AM
Achillion (ACHN) Announces That Janssen Pharmaceutical Has Initiated A Phase IIa Study To Evaluate The Combination Of AL-335, Odalasvir (ACH-3102), And Simeprevir For The Treatment Of Genotype 1 Chronic HCV 10/16/2015 7:43:41 AM